OAOlisaemeka Zikora Akunne

Olisaemeka Zikora Akunne

*This is an algorithmically generated author record based on publicly available information.

Olisaemeka Zikora Akunne has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibiotic resistance: The growing threats and potential solutions

    by Olisaemeka Zikora Akunne, Blessing Nkechi Emmanuel, Umar Faruk Saidu, Ayobami Sunday Akinnawo, Nasiru Ademola Adeyemi, Livia Chinaza Egoh, Malami Aishatu Muhammad, Olusegun Ayo Ade-Adekunle, Deborah Ahuoyiza Peter, Anne Amina Freitas

    Antibiotic resistance (AR) has become a critical global health crisis, threatening the efficacy of antibiotics and increasing healthcare costs, morbidity, and mortality. The One Health approach, which emphasizes the interconnectedness of human, animal, and environmental health, is increasingly recognized as an essential framework for addressing the complex drivers of AR. This review explores the mechanisms of resistance, such as genetic mutations, horizontal gene transfer, and biofilm formation, along with contributing factors such as the overuse of antibiotics in healthcare and agriculture. We assess both traditional and emerging strategies to combat AR, including antimicrobial stewardship, the development of new antibiotics, and alternative therapies such as bacteriophages, probiotics, and metal complexes. In addition, innovative approaches such as nanotechnology, combination therapies, and precision medicine are highlighted as promising tools for AR mitigation. Through case studies, this paper illustrates the effectiveness of the One Health approach in managing zoonotic diseases and antimicrobial resistance, while also underscoring the need for transdisciplinary collaboration to secure a sustainable and effective future for antibiotic use.


  • Open Access

    Innovative nanoparticle-based therapies for pancreatic neuroendocrine tumours (PNETs): advances, challenges, and future directions

    by Olisaemeka Zikora Akunne, Lynda Ify Onyebuchukwu, Maduabuchi Gabriel Azu, Jennifer Chinaza Ogwurumba


  • Open Access

    Emerging strategies in cancer immunotherapy: Expanding horizons and future perspectives

    by Olisaemeka Zikora Akunne, Ogochukwu Emilia Anulugwo, Maduabuchi Gabriel Azu

    Cancer immunotherapy has revolutionized oncology by harnessing the body’s immune system to target and eradicate malignant cells. This review delves into emerging strategies in cancer immunotherapy, focusing on novel approaches and future directions of this rapidly evolving field. Key areas of exploration include immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. ICIs, which target proteins such as cytotoxic T-lymphocyte antigen-4 and programmed cell death-1/programmed cell death ligand 1, have shown significant efficacy in various cancers, transforming clinical outcomes. CAR-T cell therapy, with its ability to genetically modify T-cells to attack cancer cells, has demonstrated remarkable success in hematologic malignancies and is being adapted for solid tumors. Cancer vaccines designed to stimulate an immune response against specific tumor antigens are also advancing with promising clinical results. Despite these advances, challenges such as immunogenicity, side effects, and treatment resistance remain. This review provides a comprehensive overview of the latest developments, clinical trials, and future perspectives in cancer immunotherapy, highlighting the potential for these strategies to redefine cancer treatment.


  • Open Access

    Emerging therapies targeting cardiovascular risk factors to prevent or delay the onset of heart failure

    by Olisaemeka Zikora Akunne, Ogochukwu Emilia Anulugwo

    Cardiovascular disease (CVD) poses a significant global health concern, contributing to nearly 30% of global deaths. Its prevalence is on the rise, necessitating a deeper understanding of associated risk factors including hypertension, cardiac hypertrophy, and diabetes. Addressing these risk factors is crucial in preventing or slowing the onset of heart failure (HF), a complex chronic condition with high morbidity and mortality rates. This review aims to explore innovative strategies for preventing or delaying HF, focusing on cardiovascular risk (CV) factors. Specifically, it delves into the link between hypertension, cardiac hypertrophy, diabetes, and HF emphasizing the importance of identifying new therapeutic approaches. A comprehensive examination of existing literature, clinical trials, and experimental models forms the basis of this review providing insights into the interconnected nature of cardiovascular risk factors and the efficacy of combination therapies. Evidence from diverse sources supports the adoption of a multifaceted approach to HF prevention. The review underscores the complex associations between hypertension, cardiac hypertrophy, diabetes, and HF highlighting the need for innovative therapeutic interventions. Clinical trials demonstrate promising outcomes with synergistic therapies such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors showcasing improved efficacy over single-agent interventions. In conclusion, adopting a multifaceted approach to HF prevention considering the interplay of various risk factors. Such an approach holds the potential for substantial benefits including simultaneous targeting of multiple pathways, individualized care, enhanced patient motivation, and reduced healthcare costs. Further research should focus on optimizing combination therapies and identifying patient population that stands to gain the most from these interventions providing a pathway towards improved cardiovascular health globally.


  • Open Access

    Evaluating the knowledge, attitude, perception, and readiness of caregivers of under 5-year-old children to accept malaria vaccine in Nigeria

    by Blessing Nkechi Emmanuel, Abubakar Nuhu Ishaq, Olisaemeka Zikora Akunne, Umar Faruk Saidu

    Emmanuel BN, et al. Clin Exp Vaccine Res. 2024 Apr;13(2):121-131. https://doi.org/10.7774/cevr.2024.13.2.121